Zhejiang Sunflower continues progress on major asset restructuring

Zhejiang Sunflower Great Health Technology Co., Ltd. announced the ongoing advancement of its major asset restructuring. This involves issuing shares and paying cash to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beide Pharmaceutical Co., Ltd., along with raising supporting funds. The company's stock was halted from September 8, 2025, for this purpose and resumed trading on September 22, 2025.

The proposed transaction is classified as a connected transaction and a major asset restructuring. As of December 19, 2025, auditing, evaluation, and due diligence for the transaction are progressing in an orderly manner, with the company engaging in ongoing communication with relevant parties.

The company highlighted that the transaction remains subject to further review and approval by its board of directors and shareholders' meeting, as well as necessary regulatory approvals. Investors are advised to monitor subsequent announcements for updates and to be aware of the inherent investment risks.